Table 3.
Progression-free survival (according to the CHAARTED and STAMPEDE definitions of progressive disease) age, PSA, comorbidities and bone metastases
|
|
Number of patients
|
Number of events
|
HR, 95%CI, P value (univariate)
|
HR, 95%CI, P value (multivariate)
|
| Age, yr (median) | ||||
| ≤ 68 | 48 | 21 | 1.00 | 1.00 |
| > 68 | 46 | 15 | 0.78, 0.40-1.51, 0.45 | 0.83, 0.42-1.67, 0.61 |
| PSA (median) | ||||
| ≤ 180 | 48 | 12 | 1.00 | 1.00 |
| > 180 | 46 | 24 | 2.86, 1.39-5.87, 0.0041 | 2.51, 1.21-5.19, 0.013 |
| Comorbidities | ||||
| No | 44 | 15 | 1.00 | 1.00 |
| Yes | 50 | 21 | 1.15, 0.59-2.23, 0.68 | 1.19, 0.60-2.36, 0.63 |
| Distant metastases | ||||
| No | 19 | 3 | 1.00 | 1.00 |
| Yes | 75 | 33 | 3.36, 1.03-10.96, 0.045 | 2.60, 0.78-8.65, 0.12 |